Scriven Mary, Dinan Timothy G, Cryan John F, Wall Mary
Department of Psychiatry, University College Cork, T12 DC4A Cork, Ireland.
APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland.
Diseases. 2018 Sep 6;6(3):78. doi: 10.3390/diseases6030078.
The microbiome gut brain (MGB) axis consists of bidirectional routes of communication between the gut and the brain. It has emerged as a potential therapeutic target for multiple medical specialties including psychiatry. Significant numbers of preclinical trials have taken place with some transitioning to clinical studies in more recent years. Some positive results have been reported secondary to probiotic administration in both healthy populations and specific patient groups. This review aims to summarise the current understanding of the MGB axis and the preclinical and clinical findings relevant to psychiatry. Significant differences have been identified between the microbiome of patients with a diagnosis of depressive disorder and healthy controls. Similar findings have occurred in patients diagnosed with bipolar affective disorder and irritable bowel syndrome. A probiotic containing , , and produced a clinically measurable symptom improvement in patients with depressive disorder. To date, some promising results have suggested that probiotics could play a role in the treatment of stress-related psychiatric disease. However, more well-controlled clinical trials are required to determine which clinical conditions are likely to benefit most significantly from this novel approach.
微生物群-肠道-脑（MGB）轴由肠道与大脑之间的双向通信途径组成。它已成为包括精神病学在内的多个医学专业的潜在治疗靶点。近年来，大量的临床前试验已经开展，其中一些已过渡到临床研究。在健康人群和特定患者群体中，均有报告称益生菌给药后取得了一些积极成果。本综述旨在总结目前对MGB轴的认识以及与精神病学相关的临床前和临床研究结果。已确定诊断为抑郁症的患者与健康对照者的微生物群存在显著差异。在诊断为双相情感障碍和肠易激综合征的患者中也有类似发现。一种含有[具体成分]的益生菌使抑郁症患者的症状在临床上得到了可测量的改善。迄今为止，一些有前景的结果表明益生菌可能在应激相关精神疾病的治疗中发挥作用。然而，需要更多严格对照的临床试验来确定哪些临床病症可能从这种新方法中获益最大。
